Skip to content
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Artivion, Inc. AORT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
3 YEARS OF DIVIDEND GROWTH
$441.3M
▲ 13.6% YoY
$9.8M
$839,000
▼ 92.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. As of December 31, 2025, the company had approximately 1,800 employees, most of whom are located in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany. The company has employees in almost 30 different countries. The company has two reportable segments organized according to its products and services: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.

Written from the business description in ARTIVION, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.

Growth

USD 441.3M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 441.3 · Net income 9.8
200M400M
2009201220152018202120242025
Compound annual growth
+12.0%
+11.8%
+11.7%
+9.3%
+9.3%
+6.2%
+4.1%
+2.7%
−7.8%
−9.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.8% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

2 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 7.6% · Net 2.2%
5%10%-5%
200920172025
ROE
FY2025 · ROE 2.7%
5%10%-5%-10%
200920172025
Three returns, three denominators.

Each USD of equity produced 3 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.8
10M20M-10M-20M
200920172025
Net buybacks $M Dividends $M
FY2015 · Dividends 3.4 · Net buybacks ·
2.5M5.0M-0.3M-0.6MDividendsNet buybacks
2009201020112012201320142015

Total assetsUSD 884.8M
EquityUSD 448.2M
CashUSD 64.9M
Gross debtUSD 215.1M
Net debtUSD 150.2M
Current ratio3.53×

Net debt stands at 34% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
AORT, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.40.40.40.30.30.30.30.30.20.20.10.10.10.10.10.10.1
Operating income $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EBITDA $B0.10.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.0−0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.0
Net income $B0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.00.00.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $0.21−0.32−0.75−0.48−0.38−0.440.05−0.080.110.320.140.250.570.280.260.140.30
Dividend / sh $◌◌◌◌◌◌0.000.000.000.000.120.120.110.05◌◌◌
Payout %——————————85451817———
ROE %2.7−4.8−10.8−6.6−4.7−5.40.6−1.01.55.92.65.011.96.46.33.57.9

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image